Clearside Biomedical

Clearside Biomedical Net Tangible Assets

Delisted

The Net Tangible Assets of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -38.86 M USD. In the previous year, Net Tangible Assets was -15.91 M USD — a change of 144.19% (lower).

Net Tangible Assets

-38.86 MUSD

YoY

144.19%

Last updated:

Net Tangible Assets of Clearside Biomedical is 2024 -38.86 M USD. Net Tangible Assets of Clearside Biomedical was 2023 -15.91 M USD. It decreases by 144.19% lower compared to the previous year.

The Clearside Biomedical Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2017
21.42 M USD
Jan 1, 2018
23.62 M USD
Jan 1, 2019
11.16 M USD
Jan 1, 2020
8.76 M USD
Jan 1, 2021
37.98 M USD
Jan 1, 2022
10.61 M USD
Jan 1, 2023
-15.91 M USD
Jan 1, 2024
-38.86 M USD
The Clearside Biomedical Net Tangible Assets history
YEARNet Tangible AssetsYoY
-38.86 MUSD+144.19%
-15.91 MUSD-249.97%
10.61 MUSD-72.06%
37.98 MUSD+333.56%
8.76 MUSD-21.51%
11.16 MUSD-52.75%
23.62 MUSD+10.27%
21.42 MUSD-70.11%
71.66 MUSD+572.23%
10.66 MUSD+39.90%
7.62 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Net Tangible Assets of Clearside Biomedical is -38.86 M USD in 2024.

Net Tangible Assets of Clearside Biomedical changed from -15.91 M USD to -38.86 M USD, representing a 144.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical